Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 5 3 3

+8 more TTM periods

ROE
(929.31%) (273.55%) (213.45%) (205.90%)
ROA
(16.66%) (15.65%) (53.45%) (44.70%)
ROIC
(22.22%) 0.00% (93.25%) (108.83%)
Return on Tangible Assets
(44.27%) (39.14%) (167.41%) (142.61%)
Average Days of Receivables
71.28 66.94 80.86 72.29
Free Cash Flow per Share
(0.26) (0.23) (0.40) (0.44)
Free Cash Flow
(80.48) (71.21) (118.92) (131.44)
Capital Expenditures
37.57 40.63 (7.71) (8.65)
Other line items
Cash ROIC
(9.49%) (25.58%) (12.78%) (13.41%)
Accounts Receivable Turnover
5.03 5.25 5.08 5.15
Accounts Payable Turnover
5.91 7.24 6.11 8.11
Inventory Turnover
1.76 1.91 2.11 1.94
Average Days of Payables
69.25 49.65 66.37 51.79
Days of Inventory on Hand
220.04 186.16 157.49 168.25
Tax Rate
0.01 0.01 0.00 0.00
Research and Development Expense of Revenue
55.47% 54.90% 60.81% 65.91%
Selling, General and Administrative Expense of Revenue
81.43% 82.78% 88.43% 96.44%
Share Based Compensation of Revenue
21.53% 23.07% 26.04% 31.12%
Interest Coverage
(18.15) (19.16) (79.65) (83.51)
Operating CF/Net income
0.90 0.87 0.20 0.24
Depreciation/Fixed assets
0.58 0.61 16.44 22.27
Capex/Depreciation
2.39 2.76 (0.02) (0.02)
Revenue per Share
0.51 0.52 0.53 0.51
Operating CF per Share
(0.38) (0.37) (0.37) (0.41)
Capex per Share
0.12 0.13 (0.03) (0.03)
Capex to Sales
(0.24) (0.25) 0.05 0.06

Fold the line items

Columns are period end dates